Table I.
Characteristics of the included studies.
| Author/Year | No. of patients | BC subtype | AR assessment | Concomitant/ experimental treatment | Definition of AR | Prognostic value |
|---|---|---|---|---|---|---|
| Kensler /2019 | 3021 | ER+ | IHC | Tamoxifen/ Letrozole | ≥ 1% | Not associated with prognosis |
| Lehmann /2014 | 50 | TNBC | FFPE sections, DAKO clone AR411 | No | >30% | Favorable in combination AR antagonists with PI3K/mTOR inhibitors |
| Conde /2004 | 39 | CIS, infiltrating carcinoma | IHC+ immunobloting | Tamoxifen | No | Presence of DAX-1 may interfere with endocrine therapy |
| Guiu /2018 | 333 | TNBC | IHC | No | 1% | AR+/ FOXA1+ worse outcome |
| Dieci /2019 | 263 | TNBC | IHC | Neo/adjuvant treatment | 1% | AR+ is associated with worse outcome |
| Elebro /2017 | 910 | BC | IHC | Yes | >10% | AR+/ER− worse prognosis |
| Park /2009 | 413 | BC | IHC | No | ≥ 10% | lower tumor burden and favorable differentiation |
| Gonzalez /2008 | 83 | BC | IHC | No | >10% | AR are represented in breast cancer and are correlated with the expression of some MMPs and TIMP-2. |
| Caiazza /2016 | 2091 | TNBC | IHC | Enzalutamide | >10% | Provide an alternative treatment for patients with AR-positive TNBC. |
| Traina /2018 | 57 | TNBC | IHC | Enzalutamide | ≥ 10% | Clinical efficacy, well tolerated |
| Gucalp /2013 | 424 | ER/PgR-negative | IHC | Bicalutamide | ≥ 10% | Efficacy, minimally toxic androgen blockade |
| Castellano /2010 | 953 | ER+ | IHC | No | 10% | Prognostic factor of better outcome |